Agentix Corp. SEC filings AGTX
Agentix Corp. has 153 filings in SEC EDGAR's recent list, going back to Apr 1, 2014. Its latest annual report, Form 10-K, was filed on Jul 1, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jun 14, 2022 (officer or director change). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14C | Information statement | Jun 27, 2019 | Jun 26, 2019 |
| PRE 14C | Filing | Jun 17, 2019 | Jun 17, 2019 |
Showing 2 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- AGTX (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- Dana Point, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1603345
- Former names
- FairWind Energy Inc. (until Jun 27, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.